The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices to protect customer data.

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, including its biobank of customer genetic samples, have been purchased by American biotechnology company Regeneron Pharmaceuticals for a cool $256 million, the highest bid submitted in the once-hot startup’s bankruptcy auction.